

**WO02057478**

**Publication Title:**

**METHODS AND COMPOSITIONS FOR EXTRACTING PROTEINS FROM CELLS**

**Abstract:**

The present invention relates to a process of releasing a protein, recombinant or otherwise, from a cell. The process of the present invention involves contacting a host cell containing a protein of interest with a solution comprising one or more detergents and one or more reducing agents. The methods of the invention are particularly suitable to large scale production of recombinant products.

-----  
Data supplied from the esp@cenet database - <http://ep.espacenet.com>

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 July 2002 (25.07.2002)


PCT

(10) International Publication Number  
**WO 02/057478 A1**

- (51) International Patent Classification<sup>7</sup>: C12P 21/06, (74) Agents: FRIEBEL, Thomas, E. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).  
C12N 1/00, 1/14, C07K 1/20
- (21) International Application Number: PCT/US02/01670
- (22) International Filing Date: 18 January 2002 (18.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/766,043 19 January 2001 (19.01.2001) US
- (71) Applicant: COVANCE BIOTECHNOLOGY SERVICES [US/US]; 6051 George Watts Hill Drive, Research Triangle Park, NC 27709-3865 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventor: SHEPARD, Scot, R.; 1028 Swift Creek Drive, Clayton, NC 27520 (US).

[Continued on next page]

(54) Title: METHODS AND COMPOSITIONS FOR EXTRACTING PROTEINS FROM CELLS



(57) Abstract: The present invention relates to a process of releasing a protein, recombinant or otherwise, from a cell. The process of the present invention involves contacting a host cell containing a protein of interest with a solution comprising one or more detergents and one or more reducing agents. The methods of the invention are particularly suitable to large scale production of recombinant products.

WO 02/057478 A1



**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**METHODS AND COMPOSITIONS FOR EXTRACTING PROTEINS FROM CELLS****1. TECHNICAL FIELD OF THE INVENTION**

The present invention relates to a process of recovering intracellular proteins and other molecules from a cell.

**5 2. BACKGROUND OF THE INVENTION**

It is desirable to lyse cells grown as production hosts containing a protein or other molecule of interest to recover any desired intracellularly produced product.

Conventional ways to kill and lyse such cells include the  
10 use of heat (U.S. Pat. No. 4,601,986 to Wegner, et al.),  
osmotic pressure (U.S. Pat. No. 4,299,858 to Aubert, et al),  
enzymes which break down the cell walls or membranes (U.S.  
Pat. No. 3,816,260 to Sugiyama, U.S. Pat. No. 3,890,198 to  
Kobayashi, et al. and U.S. Pat. No. 3,917,510 to Kitamura,  
15 et al.) and mechanical disruption of the cell wall by, for  
example, high pressure homogenization. The disclosures of  
the above patents are incorporated herein by reference.

Also, detergents have been utilized to lyse the  
cell wall. For example, yeast protein extraction reagent  
20 (Y-PER®), sold by Pierce Chemical Company, contains a  
detergent to provide a gentle means of cell lysis that is  
not detrimental to the protein of interest. However, Y-PER®  
is intended to be used as a laboratory bench reagent, not as  
a reagent useful for the large scale production of proteins,  
25 and is costly. For these reasons, Y-PER® has not gained

acceptance as a useful reagent for the large scale

production of recombinant protein from host cells.

There is a need in the art for a process that can be used to easily cause the release of proteins from host cells without harming the desired protein and with a minimum of process steps. The method of cell lysis should not directly or indirectly lead to denaturation of the desired product and the method should be consistent with subsequent processing requirements and with large scale production.

### 3. SUMMARY OF THE INVENTION

The present invention relates to a process of releasing a protein, recombinant or otherwise, from a cell. The process of the present invention involves contacting a host cell containing a protein of interest with a solution comprising one or more detergents and one or more reducing agents. The addition of one or more reducing agents facilitates the recovery of proteins in their native conformations. The methods of the invention are particularly suitable to large scale production of recombinant products. The methods of the invention comprise four basic steps: adjustment of bulk solution conditions to achieve a permissive environment, contact of cells with a reducing agent either before, during or after contact of the cells with certain charge-modified hydrocarbons, and finally clarification of the extract to produce a fraction suitable for formulation or further processing. Typically, the reducing agent and the detergent are added sequentially in

any order, resulting in the concurrent exposure of the cells-

to the reducing agent and the detergent.

In a particular embodiment, the one or more detergents are amphipathic, charged amines or amine oxides coupled to hydrocarbon chains of varying lengths. In a preferred embodiment, the one or more detergents used are selected from the group consisting of, tributylphosphate, dimethyldecylamine, dimethyltridecylamine, dimethylundecylamine, dimethyldidecylamine, dimethyltetradecylamine, dimethylhexadecylamine, dimethyldecylamineoxide, dimethylundecylamineoxide, dimethyldidecylamineoxide, dimethyltetradecylamineoxide and dimethyltridecylamineoxide. Preferably, the detergent is not dimethyltridecylamine.

Detergents may be used at concentrations ranging from 0.01% up to their solubility limit. Preferably, the concentration of the detergents ranges from 0.05% to 5%, 0.1% to 2%, or is approximately 0.5% of the total solution. When added to cells suspended in buffer, the detergent is preferably at a higher concentration than the final concentration at which the cells are lysed. Preferably, the detergent is at least at a 2 fold, 5 fold, 10 fold or 100 fold higher concentration.

In a particular embodiment, the one or more reducing agents are agents are those reducing agents that reduce disulfide bonds and/or maintain sulfhydryl residues in the reduced form. Any such reducing agent or agents may

be used. In a preferred embodiment, the one or more

reducing agents used are selected from the group consisting of, Dithiothreitol (DTT); Dithioerythritol (DTE); Cysteine (Cys) and Tris 2-carboxyethylphosphine (TCEP).

5 Reducing agents may be used at concentrations ranging from 0.1 mM to 100 mM, 1 mM to 25 mM, 2 mM to 10 mM, or about 5 mM. When added to cells suspended in buffer, the reducing agent is preferably at a higher concentration than the final concentration at which the cells are lysed.

10 Preferably, the detergent is at least at a 2 fold, 5 fold, 10 fold or 100 fold higher concentration.

In addition to the one or more detergents and reducing agents, in a preferred embodiment, the cells are also contacted with glycerol. Preferably, the glycerol  
15 concentration is at least 0.6%, or ranges from 0.6% to 20%, 0.6% to 15%, 0.6% to 12%, 0.6% to 6%, 0.6% to 3%, or 0.6% to 1%.

The pH of the solution can range from pH 2 to pH 12. Preferably, the solution is at a pH ranging from pH 5.0  
20 up to pH 8.0. More preferably, the pH ranges from pH 5.5 to 7.4, from pH 6 to 7.4, from pH 7.0 to 7.4, or is approximately pH 7.3.

The recovery of protein from the cells with the solution of the invention can be carried out at a  
25 temperature of from about 2°C to about 50°C. Preferably, the temperature is from about 2°C to about 30°C, about 2°C

to about 20°C, about 2°C to about 10°C, about 3°C to about 10°C, about 4°C, about 25°C, or at room temperature.

The "host cells" are cells containing a protein of interest. A "protein of interest" is any protein present in a host cell that one desires to release from the host cell and, optionally, subsequently isolate or purify.

Preferably, the protein of interest is a recombinant protein. In a preferred embodiment, the protein of interest has a molecular weight of less than 100 kD. In a further preferred embodiment, the protein of interest has a molecular weight of between 5 and 75 kD, preferably about 50 kD. The host cells may be of any type, preferably mammalian, bacterial, yeast, fungal, plant, avian, or reptilian. Most preferably, the host cells are yeast cells.

In a particular embodiment, the yeast cells are of the species *Pichia pastoris*.

In addition to releasing proteins from host cells, the composition of the invention may be used to release other molecules from host cells including nucleic acids, lipids, vitamins, small molecules and other cell, cytosolic, or organelle derived molecules or molecular complexes.

#### 4. BRIEF DESCRIPTION OF THE DRAWINGS

The various features of the invention may be more fully understood from the following description when read together with the accompanying drawings.

Fig. 1 . Extraction of rBoNTA(Hc) with and without DTT at 4°C and 21°C -- Fig. 1 shows the effect of time,



temperature and reducing agent on the recovery of a protein of interest from a host cell.

## 5. DETAILED DESCRIPTION OF THE INVENTION

5 The present invention relates to a process of releasing a protein, recombinant or otherwise, from a cell. The methods of the invention comprise four basic steps: adjustment of bulk solution conditions to achieve a permissive environment, contact of cells with a reducing agent either before, during or after contact of the cells  
10 with certain charge-modified hydrocarbons, and finally clarification of the extract to produce a fraction suitable for formulation or further processing.

In a particular embodiment, solution conditions are adjusted by 1) sedimentation of the cellular fraction  
15 followed by re-suspension, 2) by solution exchange using filtration methods, 3) by direct modification of the existing solution conditions, or 4) by other means of solvent exchange. Cells suspended in an appropriate solution are then contacted with certain amphipathic molecules that  
20 cause disruption of the cell membrane thus allowing the cell contents to diffuse through the cell wall and into the extracellular medium. Cellular debris is then separated from the soluble extract by sedimentation, flocculation, filtration, chromatographic, or other separation methods.

25 In a preferred embodiment, yeast cells, for example *Pichia pastoris*, taken directly from a fermentation process are concentrated and then exchanged from growth

medium into a specific buffered solution by tangential flow  
filtration using microporous membranes. The concentrated  
and solution adjusted cells are then contacted with  
dimethylamine and/or dimethylamine oxide compounds with  
5 alkyl chains of varying length, depending on cell type and  
solution conditions. In addition, the solution may contain  
detergents, such as Triton X-100 or polyols, such as  
glycerol, that enhance the extraction process. The extract  
of intracellular molecules is then separated from the  
10 remaining insoluble slurry by depth filtration, for example,  
using diatomaceous earth in a plate and frame filter press.

Solution permissivity is dependent on pH,  
temperature, ionic strength, time, cell concentration and  
the addition of certain components that enhance the  
15 effectiveness or kinetics of cell disruption or molecular  
stability. Solution pH can be from pH 3 to 11, more  
preferably 5 to 8, or approximately 6.5 to 8.0. Temperature  
can range from about 2°C to 50°C, or more preferably 2°C to  
30°C. Ionic strength can vary from hypotonic to hypertonic  
20 conditions, most preferably 0.001 to 3000 mM sodium  
chloride, or other salt, depending on the properties of the  
desired target molecule. In preferred embodiments, the  
ionic strength is below 350 mM, below 250mM, below 150mM,  
below 100 mM, below 50 mM, and below 10 mM, but not lower  
25 than 5 mM, 1 mM, .01 mM or .001 mM.

The "host cells" are cells containing a protein of  
interest. A "protein of interest" is any protein present in

a host cell that one desires to release from the host cell

and, optionally, subsequently isolate or purify.

Preferably, the protein of interest is a recombinant

protein. When the protein of interest is a recombinant

5 protein, it can be produced by any method known in the art.

Typically, a gene that encodes the recombinant protein that

is desired is inserted into a recombinant molecule. The

polynucleotides constituting the gene may be obtained by

standard procedures known in the art, such as from cloned

10 DNA (such as a DNA "library"), chemical synthesis, cDNA

cloning, or by the cloning of genomic DNA, or fragment

thereof, from a desired cell as described in Sambrook, J.,

et al., Molecular Cloning: A Laboratory Manual, 2d Edition,

Cold Spring Harbor Laboratory Press (1989).

15 Once the gene encoding the recombinant protein has

been isolated, it is inserted into an appropriate cloning

vector. A large number of vector-host systems known in the

art may be used. Possible vectors include, but are not

limited to, plasmids or modified viruses, provided that the

20 vector system is compatible with the host cell used. The

vectors that can be used include, for example, an *E. coli*

cloning vector, bacteriophages such as lambda derivatives,

plasmids such as pBR322 derivatives or pUC plasmid

derivatives. The cloning vector can be introduced into host

25 cells via transformation, transfection, infection,

electroporation, etc., so that many copies of the gene

sequence are generated.

## Transformation of host cells with a cloning vector

that incorporates the gene enables the generation of multiple copies of the gene. Therefore, the gene may be obtained in large quantities by growing transformants, isolating the cloning vector from the transformants and, when needed, retrieving the inserted gene from the isolated cloning vector. Once sufficient copies of the gene sequence have been generated, the gene encoding the recombinant protein, or a functionally active fragment or other derivative thereof, can be inserted into an appropriate recombinant molecule. The recombinant molecule is a polynucleotide expression vector that contains the necessary elements for the transcription and translation of the inserted protein-coding sequence of the recombinant protein. Preferably, the expression vector also includes an origin of replication. The necessary transcription and translation signals can also be supplied by the native gene and/or its flanking regions.

Once a recombinant molecule has been prepared, it is inserted into an acceptable host cell which will grow and divide to produce clones. A variety of host cell-vector systems may be utilized to express the recombinant protein. Suitable host cell-vector systems include, for example, bacterial expression systems, mammalian cell systems infected with a virus, such as a vaccinia virus or adenovirus, insect cell systems infected with a virus such as a baculovirus, microorganisms such as yeast containing

yeast vectors, and bacteria transformed with bacteriophage

DNA, plasmid DNA or cosmid DNA.

Recombinant molecules containing the gene of interest can be identified by PCR amplification of the desired plasmid DNA or specific mRNA, nucleic acid hybridization, presence or absence of marker gene functions and expression of the inserted sequences.

The host cells, such as *E. coli* cells, transformed with a polynucleotide that encodes a recombinant protein of interest, can be added directly to a reaction vessel. To purify and recover the recombinant protein, the host cells are concentrated to form a concentrated suspension of whole cells. The host cells can be concentrated by any method known in the art. For example, the host cells may be centrifuged. Centrifugation removes water from the host cells and concentrates the cells, forming a cell paste. Centrifugation also separates the host cells from the culture medium. The host cells may be of any type, preferably mammalian, bacterial, yeast, plant, avian, or reptilian. Most preferably, the host cells are yeast cells.

Once a concentrated suspension of cells has been obtained, the cells are contacted with a protein recovery solution. The protein recovery solution comprises one or more detergents and one or more reducing agents. In a particular embodiment, the one or more detergents are amphipathic, charged amines or amine oxides coupled to hydrocarbon chains of varying lengths. In a preferred

embodiment, the one or more detergents used are selected

from the group consisting of, tributylphosphate,  
dimethyldecylamine, dimethyltridecylamine,  
dimethylundecylamine, dimethyldidecylamine,  
5 dimethytetradecylamine, dimethylhexadecylamine,  
dimethyldecylamineoxide, dimethylundecylamineoxide,  
dimethyldidecylamineoxide, dimethytetradecylamineoxide and  
dimethyltridecylamineoxide. Preferably, the detergent is  
not dimethyltridecylamine. Detergents may be used at  
10 concentrations ranging from 0.01% up to their solubility  
limit. Preferably, the concentration of the detergents  
ranges from 0.05% to 5%, 0.1% to 2%, or is approximately .5  
% or 1% of the total solution. Preferably, the detergents,  
just prior to their addition to the host cells, are at least  
15 90%, at least 95% or at least 99% pure. In preferred  
embodiments, the detergents to be added are at least 3 fold,  
at least 5 fold, at least 10 fold, at least 50 fold, at  
least 100 fold, at least 200 fold the final concentration of  
the detergents after addition and dilution in the cell  
20 suspension.

In a particular embodiment, the one or more  
reducing agents are agents are those reducing agents that  
reduce disulfide bonds and/or maintain sulfhydryl residues  
in the reduced form. Any such reducing agent or agents may  
25 be used. In a preferred embodiment, the one or more  
reducing agents used are selected from the group consisting

of, Dithiothreitol (DTT); Dithioerythritol (DTE); Cysteine (Cys) and Tris 2-carboxyethylphosphine (TCEP).

Reducing agents may be used at concentrations ranging from 0.1 mM to 100 mM, 1 mM to 25 mM, 2 mM to 10 mM, or about 5 mM. When added to cells suspended in buffer, the reducing agent is preferably at a higher concentration than the final concentration at which the cells are lysed.

Preferably, the detergent is at least at a 2 fold, 5 fold, 10 fold or 100 fold higher concentration. The effectiveness of the reducing agent can be determined by titration of free

sulphydryls using Ellman's reagent. Preferably, the reducing agent is Dithiothreitol. Preferably, the reducing agent concentration is 5 mM. Preferably, the reducing agent

is added to the extraction buffer just prior to the addition of the detergent followed by incubation at 4°C for 12 hours.

However, the reducing agent may be added before or after the detergent. Preferably, the reducing agent is added prior to the addition of the detergent. In another embodiment, the

detergent and reducing agent are added together. In another embodiment, the detergent is added prior to the reducing agent.

In addition to the one or more detergents and reducing agents, in a preferred embodiment, the cells are also contacted with glycerol. Preferably, the glycerol

concentration is at least 0.6%, or ranges from 0.6% to 20%, 0.6% to 12%, 0.6% to 6%, 0.6% to 3%, or 0.6% to 1%.

Preferably, the glycerol, just prior to addition to the host

cells, is at least 90%, at least 95% or at least 99% pure.

In preferred embodiments, the glycerol to be added is at least 3 fold, at least 5 fold, at least 10 fold, at least 50 fold, at least 100 fold, at least 166 fold the final concentration of the glycerol after addition and dilution in the cell suspension.

Preferably, the solution is at a pH ranging from pH 5.0 up to pH 8.0. More preferably, the pH ranges from pH 5.5 to 7.4, from pH 6 to 7.4, from pH 7.0 to 7.4, or is approximately pH 7.3.

The recovery of the protein of interest from the cells with the solution of the invention can be carried out at a temperature of from about 2°C to about 50°C. Preferably, the temperature is from about 2°C to about 30°C, 2°C to about 20°C, 2°C to about 10°C, about 4°C, about 25°C, or at room temperature.

The amount of the detergent and reducing agent solution of the invention used per gram of cells can vary greatly, for example, anywhere from 0.5 mL of detergent and reducing agent solution per gram of cells to 20 mL per gram may be used. Preferably, 2.5 - 5.0 mL detergent and reducing agent solution per gram of cell paste is used.

The amount of time allowed for lysis of the cells after contacting said cells with the protein recovery solution may be determined by one of skill in the art. For example, cells may be incubated in the presence of the protein recovery solution for 40 minutes up to 72 hours,



Shorter and longer times are also appropriate. In general, the amount of time can be increased when the concentration of detergent is low and decreased when the amount of

5 detergent is high. For example, a protein recovery solution with a 1% detergent concentration is effective after 40 minutes, while a protein recovery solution with a 0.1% detergent concentration should be incubated for 150 minutes or longer. For optimal recovery of protein, the exact  
10 amount of time necessary can be determined by a simple time-course experiment at a given concentration of detergent, where concentration of the protein of interest released to the medium is determined over time. After a certain time point, no further increase in released protein will be  
15 observed. This time point is the optimal time necessary for lysis of the cells with the chosen concentration of detergent.

After lysis of the cells, the solution can be centrifuged to collect cellular debris in the pellet,  
20 leaving the released protein of interest in the supernatant. The supernatant may be processed according to methods known to those of skill in the art to further isolate and purify the protein of interest. The methods utilized to further isolate and/or purify the protein of interest are highly  
25 dependent upon the characteristics and properties of the particular protein of interest, and must be determined for each protein. In a particular embodiment, the protein of

interest has reactive sulfhydryls. In a particular embodiment, the protein of interest, in its native conformation, has one or more disulfide bonds. In a particular embodiment, the protein of interest is purified in a reduced form, e.g., with free sulfhydryl groups. In a particular embodiment, the protein isolated in a reduced form is folded after purification into its native, oxidized conformation. For methods of folding proteins, see Chaudhuri JB, Refolding recombinant proteins: process strategies and novel approaches. Ann N Y Acad Sci 1994 May 2;721:374-85, incorporated herein in its entirety by reference.

In a preferred embodiment, the method of the invention is applied to a large scale process of recovering a biomolecule. A large scale process is a process involving large amounts of host cell biomass. In preferred embodiments, the amount of biomass processed in a single batch according to the methods of the invention is from 1 kg to 50,000 kg, 1000 kg to 20,000 kg, 5000 kg to 10,000 kg, or about 40 kg, 100 kg, 1000 kg or 10,000 kg. In another embodiment, the amount of biomass is greater than 1 kg, greater than 40 kg, greater than 100 kg, greater than 1000 kg, greater than 5000 kg, greater than 10,000 kg, or greater than 20,000 kg. The host cells are generally in fermentation broth at the beginning of the process. The host cells are concentrated in the fermentation broth, by, for example, centrifugation or tangential flow filtration,

then the fermentation broth exchanged with 60 mM sodium phosphate, 50 mM NaCl, 5 mM EDTA, pH 7.3 (buffer). The exchange can be performed by any means known to one of skill in the art, for example, by tangential flow filtration using 0.45  $\mu$ m membrane. The concentrated biomass can be maintained at a constant volume while buffer is added to the biomass at a rate equal to the rate at which liquid was removed from the biomass by the filtration process. A buffer exchange of greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, 95%, greater than 95% or approximately 100% may be used. Preferably, the exchange is 90% or more. For example, for 7.6 liters of fermentation broth containing approximately 3 kg of cells, approximately 27 L of buffer may be processed as above which results in a buffer exchange of > 95%. The concentrated and buffer exchanged biomass is then modified by the addition of reducing agent, detergent and other compounds, for example, glycerol and tetradecyldimethylamine to concentrations of 5mM, 6.0% final weight and 0.5% final weight, respectively. The added compounds may be added separately or mixed and added together. Other concentrations, as recited above, may also be used. The mixture may then be incubated with agitation. This incubation may be for any appropriate time and temperature, for example, for 14.5 h at 19°C. The actual concentrations of reducing agents, detergents, time and temperature for any given extraction may be readily determined by one of skill

in the art. After incubation, the soluble fraction of the mixture contains large amounts of protein, nucleic acids, lipids and other molecules previously restricted to the cell membrane and cytoplasm. The mixture may be centrifuged, for example at 4000 x g for 30 minutes. The supernatant fraction may then be further processed by, for example, filtration through a 1.2  $\mu$ m and 0.2  $\mu$ m filters in series.

The following Examples illustrate the preferred embodiments of the process of the present invention and is not limiting of the specification and claims in any way.

## 6. EXAMPLES

### 6.1 LARGE SCALE RELEASE OF RECOMBINANT PRODUCT

*Pichia pastoris* fermentation broth (12.6 Kg) containing 24.4% biomass by wet weight, having a conductance of 30.2 mS/cm and pH of 4.86, was concentrated to 7.6 L. The concentrated biomass was then exchanged into 60 mM sodium phosphate, 50 mM NaCl, 5 mM EDTA, pH 7.3 (buffer) by tangential flow filtration using 0.45 m<sup>2</sup> of 0.45  $\mu$ m membrane. The concentrated biomass was maintained at 7.6 L while buffer was added to the biomass at a rate equal to the rate at which liquid was removed from the biomass by the filtration process. Approximately 27 L of buffer were processed as above which results in a buffer exchange of > 95%. The concentrated and buffer exchanged biomass was then modified by the addition of glycerol and tetradecyldimethylamine, separately, to concentrations of 6.0 and 0.5 final weight percent, respectively. The mixture

WO 02/057478 PCT/US02/01670  
was then incubated with agitation for 14.5 h at 19 C. At

this point the soluble fraction of the mixture contained large amounts of protein, nucleic acids, lipids and other molecules previously restricted to the cell membrane and cytoplasm. The mixture was then centrifuged at 4000 x g for 30 minutes. The supernatant fraction was then further processed by filtration through a 1.2  $\mu$ m and 0.2  $\mu$ m filters in series. The resulting clarified extract contained approximately 15 g/L of total protein and 0.8 g/L of the specific heterologous protein of interest. The clarified extract also contained significant quantities of ribonucleic acid, deoxyribonucleic acid and cell derived lipids.

## 6.2 EXTRACTION OF RECOMBINANT PRODUCT OVER TIME AND AT DIFFERING TEMPERATURES

*Pichia pastoris* cells were exchanged into permissive buffer conditions and contacted with 0.5% tetradecyldimethylamine (DMA-C14) and 1% Triton X-100 and 6% glycerol. Samples of the supernatant were taken at various times after incubation at different temperatures, 4°C and 22°C. The concentration of a specific heterologous (Bot B, or rBoNTB/Hc protein) protein was then determined by an HPLC method specific for that protein. The results are shown in Figures 1 (4°C) and 2 (21°C). The heterologous is released at higher efficiency over time and at the higher temperature, although at 25 hours, the amount of protein released at the two temperatures were indistinguishable when

DMA C14 (tetradecyldimethylamine), triton and glycerol or DMA-C14 and glycerol were used. DMA C14 and Triton and DMA C14 were less effective. Other observations, not represented in Figure 1 or Figure 2, show that glycerol, Triton X-100 or buffer alone did not extract protein at a level that was detectable.

### 6.3 NON-SELECTIVE RECOVERY OF INTRACELLULAR BIOMOLECULES

*Pichia pastoris* cells were exchanged into permissive buffer conditions and contacted with 0.5% tetradecyldimethylamine (DMA-C14) and 6% glycerol. Samples were taken after incubation and after clarification (low speed centrifugation and 0.2 um filtration). The concentration of RNA, DNA, phospholipids, and total protein were measured using commercially available reagent kits. The concentration of a specific heterologous protein (rBoNTB/Hc) of interest was then determined HPLC. The results are in Table 1.

Table 1

Sample/ assay	RNA (mg/L)	DNA (mg/L)	Phospho- lipids (mg/L)	Total protein (g/L)	heterologous protein (mg/L)
extract	479	61	1000	7.5	ND
clarified extract	<8ug/mL	4	<50 ug/mL	6.7	0.36

The data show that RNA, DNA, phospholipids, a specific heterologous protein, and non-specific total protein were extracted from the cells. This shows that the method is non-selective and therefore generally applicable

for the recovery in intracellular molecules from microbial

cells. The data also show that DNA, RNA, and lipids are easily removed from the soluble protein fraction of the DMA-C14 glycerol extract (compare the extract to the clarified  
5 extract). This is in contrast to mechanical cell extraction methods that result in the formation of colloidal suspensions high in nucleic acid and lipid content. Such colloidal materials are not easily separated from the soluble protein fraction and may complicate protein  
10 purification methods. Or, on the other hand, severely limit the recovery of DNA, RNA, lipids or similar molecules if those molecules were the molecules of interest. Thus, the gentle, low shear and non-selective feature of the permeabilization method may facilitate the recovery of non-  
15 protein intracellular products such as nucleic acids, lipids, and other molecules not readily obtained from mechanical lysates.

### 6.3 RECOVERY OF INTRACELLULAR BIOMOLECULES IN THE PRESENCE 20 OF A REDUCING AGENT

*P. pastoris* cells expressing the rBoNTA(Hc) protein were suspended (350 g biomass / L extraction buffer) in a solution containing 0.5% DMA-C14 (w/w) and 6% (w/w) glycerol at pH 7.2. One sample was then incubated at 21°C  
25 and a second sample at 4°C. Dithiothreitol (DTT) was then added to a third sample to 4 mM and the sample was incubated at 21°C. DTT was added to a fourth sample to 1 mM and the

sample was incubated at 4°C. Aliquots were removed from each of the four samples at the time-points indicated (see Figure 1), the samples were clarified and the concentration of rBoNTA(Hc) was determined by HPLC. The rBoNTA(Hc) concentration was then plotted as a function of time for the four different treatments. The data are summarized in Figure 1.

Although the invention is described in detail with reference to specific embodiments thereof, it will be understood that variations which are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.



1. A method of releasing a protein of interest from host cells comprising contacting the cells with a reducing agent and a detergent, wherein the detergent is an  
5 amphipathic charged amine or an amphipathic charged amine oxide.

2. The method of claim 1, wherein the detergent is selected from the group consisting of: tributylphosphate, dimethyldecylamine, dimethyltridecylamine,  
10 dimethylundecylamine, dimethyldidecylamine, dimethytetradecylamine, dimethylhexadecylamine, dimethyldecylamineoxide, dimethylundecylamineoxide, dimethyldidecylamineoxide, dimethytetradecylamineoxide and dimethyltridecylamineoxide.

15 3. The method of claim 1, wherein the detergent is not dimethyltridecylamine.

4. The method of claim 1, further comprising the step  
20 of adding glycerol to the suspended host cells.

5. The method of claim 4, wherein the detergent comprises a final concentration of between 0.01 to 10 percent.

25 6. The method of claim 4, wherein the glycerol comprises a final concentration of between 0.6 to 15

7. The method of claim 5, wherein the glycerol comprises a final concentration of between 0.6 to 6 percent.

5

8. The method of claim 1, wherein the reducing agent is selected from the group consisting of Dithiothreitol (DTT); Dithioerythritol (DTE); Cysteine (Cys) and Tris 2-carboxyethylphosphine (TCEP).

10

9. The method of claim 8, wherein the reducing agent is at a concentration of from 0.1 mM to 100 mM.

15

10. The method of claim 1, wherein the host cells are *Pichia pastoris* cells.

12. The method of claim 1, further comprising the step of incubating the cell and detergent and reducing agent mixture from 90 minutes to 24 hours.


20

13. The method of claim 12, wherein the incubation is from 8 hours to 24 hours.

25

14. The method of claim 1, further comprising the step of incubating the cell and detergent and reducing agent mixture at a temperature of between about 3°C and about 10°C.

Figure 1



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/01670

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) : C12P 21/06; C12N 1/00, 1/14; C07K 1/20 US CL : 485/69.1, 255.1, 255.5, 804; 530/350, 412, 418, 422 According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 485/69.1, 255.1, 255.5, 804; 530/350, 412, 418, 422 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	HOROWITZ et al. Solvent/Detergent-Treated Plasma: A Virus-Inactivated Substitute for Fresh Frozen Plasma. Blood, 01 February 1992, Vol. 79, No. 3, pages 826-831, especially pages 826-827 and 830.	1-3 and 12		
X	HOROWITZ et al. Inactivation of viruses in labile blood derivatives I. disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion, 1985, Vol. 25, No. 6, pages 516-522, especially pages 516-517 and Table I.	1-3 and 12-14		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.				
<table border="0"> <tr> <td>           * Special categories of cited documents:            "A" document defining the general state of the art which is not considered to be of particular relevance            "E" earlier document published on or after the international filing date            "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)            "O" document referring to an oral disclosure, use, exhibition or other means            "P" document published prior to the international filing date but later than the priority date claimed         </td> <td>           "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention            "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone            "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art            "A" document member of the same patent family         </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family			
Date of the actual completion of the international search		Date of mailing of the international search report		
10 MAY 2002		05 JUN 2002		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer ABDEL A. MOHAMMED Telephone No. (703) 308-0196		

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US02/01670

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PIET et al. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion, 1990, Vol. 30, No. 7, pages 591-598, especially pages 59-1 592 and Table 2.	1-3 and 12-14
Y	US 5,011,915 A (YAMAZAKI) 30 April 1991, cols 4-9.	1-14
Y	US 5,407,810 A (BUILDER et al) 18 April 1995, col. 16, lines 1-17; col. 17, lines 17-23; and col. 20, lines 1-32.	1-14
A	HELENIUS et al. Solubilization of Membranes by Detergents. Biochemica et Biophysica Acta, 1975, Vol. 415 pages 29-79, especially pages 30-34, 46-62, 64-65 and 70-71 and Table IV.	1-14

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/01670

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAS ONLINE, DIALOG, MEDLINE, EMBASE, BIOSIS, WPIDS

search terms: protein extract?, yeast cell?, Pichia pastoris, detergent or tributylphosphate or TNBP or dimethyundecylamine or dimethyltetradecylamideoxide, reducing agent or dithiothritol or DDT or dithioerythritol or DTE or Cysteine or Cys or Tris 2-carboxyethylphosphine or TCEP